A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：TRANSLATIONAL NEURODEGENERATION ISSN： 2047-9158 出版频率： Continuous publication 出版社： BMC, CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW   出版社网址： https://www.biomedcentral.com/ 期刊网址： https://translationalneurodegeneration.biomedcentral.com/ 影响因子： 8.014 主题范畴： NEUROSCIENCES;    China Journals 变更情况： Newly Added by 2018 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and scope Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases. Topics of interest include but are not limited to the following areas of neurodegenerative diseases: Epidemiology and pathogenesis Research into diagnosis and prevention Research into the disease pathogenesis Development of new drugs and cell therapy Drug delivery Rehabilitation Translational Neurodegeneration offers the opportunity for scientists, clinicians and physician-scientists to publish their research and clinical trials in a journal which is applicable to their specific field. Open access All articles published by Translational Neurodegeneration are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here. As authors of articles published in Translational Neurodegeneration you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement. For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed. Article-processing charges Open access publishing is not without costs. Translational Neurodegeneration therefore levies an article-processing charge of £1690.00/$2400.00/€2040.00 for each article accepted for publication, plus VAT or local taxes where applicable. If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page. BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service. Indexing services All articles published in Translational Neurodegeneration are included in: CAS DOAJ PubMed PubMed Central Science Citation Index Expanded ​Scopus The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink. Peer-review policy Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here. Translational Neurodegeneration operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript. Edited by Shengdi Chen, Translational Neurodegeneration is supported by an expert Editorial Board. Manuscripts are reviewed by internationally recognized experts in the field, selected in part from the journal's Editorial Board. The suitability of manuscripts for publication is assessed solely on criteria of scientific excellence: final decisions are made by the Editor-in-Chief and may include accept, reject, accept following minor revision and resubmit after major revision and further review. Editorial policies The editorial policies of Translational Neurodegeneration are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China. Unless otherwise stipulated in these guidelines, all manuscripts submitted to Translational Neurodegeneration should adhere to BioMed Central's editorial policies. Citing articles in Translational Neurodegeneration Articles in Translational Neurodegeneration should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number. Article citations follow this format: Authors: Title. Transl Neurodegener [year], [volume number]:[article number]. e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Transl Neurodegener 2009, 1:115. refers to article 115 from Volume 1 of the journal. Appeals and complaints If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher. Why publish your article in Translational Neurodegeneration High visibility Translational Neurodegeneration's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.  Speed of publication Translational Neurodegeneration offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF. Flexibility Online publication in Translational Neurodegeneration gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles). Promotion and press coverage Articles published in Translational Neurodegeneration are included in article alerts and regular email updates. Some may be highlighted on Translational Neurodegeneration’s pages and on the BioMed Central homepage. In addition, articles published in Translational Neurodegeneration may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Translational Neurodegeneration. A list of articles recently press-released by journals published by BioMed Central is available here. Copyright As an author of an article published in Translational Neurodegeneration you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement). For further information about the advantages of publishing in a journal from BioMed Central, please click here. Instructions to Authors Submission guidelines Our 3-step submission process   Before you submit Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit. Make sure you are submitting to the most suitable journal - Aims and scope Understand the costs and funding options - Fees and funding Make sure your manuscript is accurate and readable - Language editing services Understand the copyright agreement - Copyright   Ready to submit To give your manuscript the best chance of publication, follow these policies and formatting guidelines. Translational Neurodegeneration publishes the following article types: Case report Research Review Short report Click the relevant link to find style and formatting information for the article you are going to submit. General formatting rules for all article types - Preparing your manuscript Make sure your submission is complete - Prepare supporting information Copyright and license agreement - Conditions of publication Read and agree to our Editorial Policies - Editorial policies   Submit and promote After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond. Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.  Who decides whether my work will be accepted? - Peer-review policy Want to submit to a different journal? - Manuscript transfers Spreading the word - Promoting your publication Submit your manuscript in Editorial Manager Editorial Board Editor-in-Chief Shengdi Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China Associate Editors Jeffrey L. Cummings, Cleveland Clinic, USA Li Cao, Ruijin Hospital Shanghai Jiaotong University School of Medicine, China Mark Hallett, National Institute of Neurological Disorders and Stroke, USA Andrew J. Lees, UCL Institute of Neurology, UK Jianfang Ma, Ruijin Hospital Shanghai Jiaotong University School of Medicine, China Suya Sun, Ruijin Hospital Shanghai Jiaotong University School of Medicine, China Jialin C. Zheng, University of Nebraska Medical Center, USA Section Editors Alzheimer’s Disease and other Neurodegenerative Dementias Fenbiao Gao, University of Massachusetts Medical School, USA Serge Gauthier, McGill University, Canada Weihong Song, The University of British Columbia, Canada Zhongcong Xie, Massachusetts General Hospital and Harvard Medical School, USA Keqiang Ye, Emory University School of Medicine, USA Parkinson’s Disease and other Movement Disorders  Shu-Leong Ho, University of Hong Kong, Hong Kong SAR, China Zixu Mao, Emory University, USA  Heinz Reichmann, University of Technology Dresden, Germany Ryosuke Takahashi, Kyoto University Graduate School of Medicine, Japan Tao Xie, University of Chicago, USA Jiawei Zhou, Chinese Academy of Sciences, China Xiongwei Zhu, Case Western Reserve University, USA Other Neurodegenerative Diseases and Neurogenetics Nobu Hattori, Juntendo University School of Medicine, Japan Xinglong Wang, Case Western Reserve University, USA Bing Yu, Royal Prince Alfred Hospital, Australia Editorial Board Angelo Antonini, San Camillo Hospital IRCCS, Italy Huaibin Cai, National Institutes of Health, USA Hongzhuan Chen, Shanghai Jiao Tong University School of Medicine, China Paul Coleman, Arizona State University, USA Matt Farrer, University of British Columbia, Canada Howard Gendelman, University of Nebraska Medical Center, USA Mark Gluck, Rutgers University, USA Glenda Halliday, Neuroscience Research Australia, Australia Joanna C. Jen, University of California, Los Angeles, USA Beom S. Jeon, Seoul National University College of Medicine, South Korea Ara S. Khachaturian, Prevent Alzheimer’s Disease 2020, USA  Debomoy Lahiri, Indiana University School of Medicine, USA Weidong Le, Baylor College of Medicine, USA Peter LeWitt, Wayne State University School of Medicine, USA Xiao-Jiang Li, Emory University School of Medicine, USA Chunfeng Liu, Soochow University, China Jun Liu, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China Xiaoguang Luo, China Medical University, China Michael S. Okun, University of Florida, USA George Perry, University of Texas at San Antonio, USA Bruce Ransom, University of Washington, Seattle, USA Olivier Rascol, University Hospital, Toulouse, France Huifang Shang, Sichuan University, China Fabrizio Stocchi, Institute for Research and Medical Care, IRCCS San Raffaele, Italy Per Svenningsson, Karolinska University Hospital, Sweden Eng King Tan, Duke-NUS Graduate Medical School, Singapore Daniel D. Truong, The Parkinson's and Movement Disorder Institute, USA Erik Wolters, VU University Medical Center, Netherlands Chengbiao Wu, University of California, San Diego, USA Zhiying Wu, Zhejiang University School of Medicine, China Pingyi Xu, Guangzhou Medical University, China Kristine Yaffe, University of California, San Francisco, USA Jing Zhang, University of Washington, Seattle, USA Michael Zigmond, University of Pittsburgh, USA Oscar S. Gershanik, Universidad de Buenos Aires, Argentina Managing Editors Jianqing Ding, Ruijin Hospital Shanghai Jiaotong University School of Medicine, China Yuyan Tan, Ruijin Hospital Shanghai Jiaotong University School of Medicine, China